The present disclosure relates, in one aspect, to use of ghrelin splice variantor an analogue thereof for the preparation of a medicament for one or more of: treatmentand/or prevention of loss of body weight and body fat, prophylaxis or treatmentof cachexia, stimulation of appetite, stimulation of food intake, stimulationof weight gain, or increasingly body fat mass, or increasing body lean mass. Anotheraspect relates to the use of a ghrelin splice variant-like compound for the preparationof a medicament for the prophylaxis or treatment of cancer cachexia in an individualin need of such treatment. Another aspect relates to the use of a ghrelin splicevariant-like compound for the preparation of a medicament for prophylaxis ortreatment of cachexia in an individual by administering a subcutaneous dosageof said medicament to the individual. A further aspect relates to the use of a ghrelinsplice variant-like compound or a pharmaceutically acceptable salt thereoffor the preparation of a medicament for stimulation of appetite in an individualby administering a subcutaneous dosage of said medicament to the individual.A further aspect relates to a number of new ghrelin splice variant-like compoundsand uses thereof, as well as to pharmaceutical compositions and medical packagingcomprising the new ghrelin splice variant-like compounds.
